First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. - Wikidata - wikimedia - TriplyDB

First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.

First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.

http://www.wikidata.org/entity/Q33918152

about

Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) ..The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer.Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study.Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience.Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer.Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy.Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.

P2860

Q24658529-2F46A26F-3D37-4164-943F-933C1C70B1F3 Q27011366-7CB248BD-9AAB-4973-8279-65C784094A0B Q30244769-6209245E-D213-47AA-BA12-132A5199B407 Q34989562-94903AC9-E8D5-454E-8342-50C1045BA1E0 Q35819857-AD8A8975-6B50-4FBA-8227-7E0E1DE86BF5 Q35920292-6456E899-89D2-4140-A3E4-14E1DC67C8AF Q36857679-B87F1655-B7A4-40E8-A563-FA04D4D62800 Q36871777-829A6228-6358-4A84-AD97-15C8C3E3179E Q38307997-9EBA176D-B605-4EFE-9FC4-C6D34953181D Q38626963-FB9C6E99-8074-40D8-800A-34979209971F Q38834979-65AF96FC-5C50-49AA-8CC8-48A589EABBDD Q40157506-4706A5C9-07B6-40E5-B5E8-44F726AFC232 Q41044367-6A431BBE-7E65-49BE-8152-038A5CF085B4 Q45305367-E94F603D-5369-4E51-B9C0-82D4C0B9327F Q48523391-E85DE315-F791-4213-B82C-AEDEE4C82959 Q52657104-44C00CF9-D096-48FF-AD95-BF8C2FBFA8DE

P2860

First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.

http://www.wikidata.org/entity/Q33918152

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

First-line bevacizumab and cap ...... : GEMCAD phase II BECOX study.

@ast

First-line bevacizumab and cap ...... : GEMCAD phase II BECOX study.

@en

type

label

First-line bevacizumab and cap ...... : GEMCAD phase II BECOX study.

@ast

First-line bevacizumab and cap ...... : GEMCAD phase II BECOX study.

@en

prefLabel

First-line bevacizumab and cap ...... : GEMCAD phase II BECOX study.

@ast

First-line bevacizumab and cap ...... : GEMCAD phase II BECOX study.

@en

P1433

Q33918152-FE56DC00-CC80-451E-8C7C-36034D0316F9

P1476

Q33918152-1A2779A8-DD33-455C-8A96-A571C2B5FA3E

P2093

Q33918152-3CF296A4-A1D8-4AA5-9F79-66A7C98AD5C4

Q33918152-559DFF15-2738-4857-8F96-53D05412B538

Q33918152-5DF096E0-73CA-434D-BDFC-4D842392656A

Q33918152-7080E99E-71E4-4AB7-A6EE-976A7596D2BB

Q33918152-80140EED-18D3-49F8-B2F2-306CAE67D737

Q33918152-8F462650-3BDE-473F-876F-C269C21DF610

Q33918152-A6221E75-BC5D-40AB-B476-0DE33C31FCA6

Q33918152-C06A643C-C13D-4FA4-B107-47FF1DC79165

Q33918152-C4F24E47-1A3A-4B88-B3E4-708DFDC3A046

Q33918152-D677EA9B-DC67-49ED-8A49-8EDA8AFC30B5

P2860

Q33918152-041F77C1-EDA2-4ED6-81C7-8CF36273E00D

Q33918152-0D5D43B7-CA49-424B-A4BE-CF3E42B9675C

Q33918152-0F353B3F-F804-4808-8855-293454B5C238

Q33918152-1FFA3754-ABDD-4525-B2E7-23CEE8261F22

Q33918152-2C23B46E-3F3B-4EC0-9F51-1A018A090978

Q33918152-2D7A912D-06AE-4939-80B4-AB5F5C474F25

Q33918152-2EC443A9-A626-46B5-AF5E-541D2DF5B943

Q33918152-307884E6-67BE-4C6B-9530-FD987D683950

Q33918152-308C1D5A-A325-4023-9A33-6DFE63E27585

Q33918152-399E8091-E5D5-4373-B65A-2F4FF49BF591

P2888

Q33918152-14A632A5-2FAF-462B-8295-802D2F790F3C

P304

Q33918152-14730F8F-B113-4D88-B6C7-6A418B35713B

P31

Q33918152-A5F98B81-FF8D-4006-BDC9-7BA604C22736

P356

Q33918152-08B50452-9AB9-429F-8E29-C8E250FE7C78

P407

Q33918152-8BEFE9D5-360F-465E-B902-75CE4D57951E

P433

Q33918152-56C26135-B5B4-4580-99C8-F9DF58CB00C6

P478

Q33918152-61FEF9D1-C379-4094-8537-BE0B81C0A136

P50

Q33918152-30275209-1E0E-4F47-856A-E71EE5E51E9F

Q33918152-C7FD04C8-C9BF-44D9-A4D5-152DCF860AD0

P577

Q33918152-2D8D3559-5769-4A3F-BEC2-B76859510341

P5875

Q33918152-2912A560-4A00-447D-AEC9-D44EC36AF5A0

P6179

Q33918152-8402D44E-CEA1-4178-B122-25B8353699D0

P698

Q33918152-BD197FBE-D3D3-4BCC-AF2A-E09DD4671F6E

P921

Q33918152-513449DC-AD70-4B7A-894F-56EA9E47F0EA

P932

Q33918152-1BDCEDAB-BB60-4D32-B2F6-34B714E34DC8

P356

P1433

British Journal of Cancer

P1476

First-line bevacizumab and cap ...... C: GEMCAD phase II BECOX study

@en

P2093

C Bosch

http://www.w3.org/2001/XMLSchema#string

C García-Girón

http://www.w3.org/2001/XMLSchema#string

E Casado

http://www.w3.org/2001/XMLSchema#string

J Aparicio

http://www.w3.org/2001/XMLSchema#string

J Feliu

http://www.w3.org/2001/XMLSchema#string

J Maurel

http://www.w3.org/2001/XMLSchema#string

M J Safont

http://www.w3.org/2001/XMLSchema#string

M Jorge

http://www.w3.org/2001/XMLSchema#string

O Serra

http://www.w3.org/2001/XMLSchema#string

P Escudero

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Global burden of hypertension: analysis of worldwide data

Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.

Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.

Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

P2888

P304

241-248

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2014.346

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Alberto Carmona-Bayonas

P577

2014-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263297529

http://www.w3.org/2001/XMLSchema#string

P6179

1001034099

http://www.w3.org/2001/XMLSchema#string

P698

24946000

http://www.w3.org/2001/XMLSchema#string

P921

P932

4102952

http://www.w3.org/2001/XMLSchema#string